

Serological Evidence and Sociodemographic Risk Factors of Recent Cytomegalovirus Infection in Pregnant Women Attending a Tertiary Hospital in Maiduguri, Nigeria

Adamu Babayo¹, Yunusa Thairu², *Idris Abdullahi Nasir², Marycelin M. Baba¹

¹Department of Medical Laboratory Science, College of Medical Science, University of Maiduguri, Borno State, Nigeria;

²Department of Medical Microbiology, University of Abuja Teaching Hospital, PMB 228, Gwagwalada, Abuja, Nigeria.

Received Nov 01, 2014; accepted Dec 16, 2014

Introduction: Human cytomegalovirus (HCMV) is able to go into latency and is the most common cause of congenital infections in humans. Its clinical manifestations range from asymptomatic forms to severe fetal damage, and in rare cases, fetal death due to abortion. This prospective cross-sectional study was designed to determine the seroprevalence of HCMV infection in pregnant women attending antenatal clinics of the University of Maiduguri Teaching Hospital, Nigeria, and to identify its possible risk factors. **Methods:** Blood samples were collected from 182 pregnant women aged 16 to 40 years. Samples were tested for anti-CMV specific IgG and IgM antibodies using the commercial ELISA Kits. A brief structured questionnaire was used to obtain some of their sociodemographic characteristics. **Results:** Seroprevalence of CMV-specific IgG and IgM were 79.1% and 2.2%, respectively. Of 182 women, 141 had previous exposure to CMV [IgG (+) IgM (-)], 3 had CMV reactivated infection [IgG (+) IgM (+)], 37 were susceptible to CMV [IgG (-) IgM (-)], and only one woman had recent infection [IgG (-) IgM (+)]. There was no significant association between seroprevalence and any of the studied sociodemographic data ($p>0.05$). **Conclusion:** The findings of this study indicated that a large number of the studied pregnant women were non-immune (susceptible) to HCMV infection, while four of them had active HCMV infection, which places their unborn children at risk of acquiring congenital HCMV infections. Therefore, it is necessary to screen pregnant women for CMV infection as part of their antenatal care and follow-up them to assess the effect that CMV might have on their fetuses. *J Med Microbiol Infect Dis*, 2014, 2 (2): 49-55.

Keywords: Congenital infection, HCMV, Serological survey, Maiduguri, Nigeria.

INTRODUCTION

Human cytomegalovirus (HCMV) belongs to the family Herpesviridae, which its members are able to remain latent in various cells of the human body for a long time [1]. Globally, CMV is a very common viral infection and one of the most common causes of congenital infections. There are some evidences indicating that CMV infection leads to miscarriage and stillbirth [2]. Even in infants who are asymptomatic at birth, hearing deficits and ocular damage may appear later and progress during the first few years of life [3, 4]. Although, infection with CMV is self-limiting in immunocompetent individuals, it is associated with high morbidity and mortality in immunocompromised individuals. Consequently, CMV establishes a latent lifelong infection, which may be reactivated by altered immune status [3, 4].

CMV was first described when inclusion bearing cells were shown by Ribbert [5, 6]. Goodpasteur and Talbert were the first to suggest that this cytomegalia (inclusion cells), could be due to a viral agent [7, 8]. Rowe *et al.* and Weller *et al.* independently isolated the human CMV strains [9, 10]. In 1960, Weller *et al.* proposed the term "cytomegalovirus" and then isolated HCMV from the urine of infants with generalized disease [10].

HCMV is especially a problem for some high risk groups, including unborn babies whose mothers become infected with HCMV during pregnancy and children or

adults whose immune systems have been weakened due to diseases or medications, such as people infected with human immunodeficiency virus (HIV) or organ transplant recipients [11]. It is a common opportunistic infection in HIV-infected individuals, and a leading cause of hearing loss, vision loss, and mental retardation among congenitally infected children. More children suffer from disabilities caused by congenital HCMV than by several better-known childhood diseases, such as Down's syndrome or fetal alcohol syndrome [12].

CMV is spread by close personal contact with people who excrete the virus in their body fluids (*e.g.* saliva, urine, breast milk, cervico-vaginal secretions, and semen), by vertical transmission, through organ transplantation, or via blood transfusion [13-15]. Mother to child transmission occurs by three routes as described by Pass (1986) [13], which include transplacental, intrauterine, and breast milk transmissions.

***Correspondence:** Idris Abdullahi Nasir

Department of Medical Microbiology, University of Abuja Teaching Hospital, PMB 228, Gwagwalada, Abuja, Nigeria.

Email: eedris888@yahoo.com

Tel/Fax: +234 (803) 0522324

Serological surveys have shown HCMV infections almost exist in every population that have been tested with seropositivity ranging from 40-100% in various parts of the world [15,17]. For example, a serological survey of over 20,000 women in London found that 54.4% of these women were seropositive for HCMV [18].

Maternal infection poses the risk of congenital CMV infection, which occurs in 0.5%-2.5% of all life births [19]. Risk of congenital infection is much higher during primary infection of the mother with transmission rate of 30%-40% compared to 0.15%-2.2% during reactivation and reinfection [20].

Seroprevalence studies among pregnant women worldwide have indicated seropositivity rates for previous infection, which ranges from 50% in highly developed countries to 100% in developing countries [21].

A serological survey conducted by Okwori *et al.* on HCMV among pregnant women in Bida, Nigeria gave a seroprevalence of 84.2%. Another study carried out on pregnant women in Lagos, Nigeria gave a seroprevalence of 97.2% [22]. The high prevalence of CMV observed in these studies conducted in Nigeria, shows that the prevalence of CMV infection in Nigeria is on the rise.

The prevalence of HCMV among pregnant women has been studied in relation to other causes of congenital infections, such as *Toxoplasma gondii* and rubella (TORCH agents). In one of these comparative studies conducted on 1972 pregnant women in western region of Turkey, HCMV was found to be the highest in prevalence with a seroprevalence of 96.4% for IgG, 0.7% IgM, and 1.9% IgG+IgM and the least for *T. gondii* with a seroprevalence of 48.3% for IgG, 0.4% IgM, and 1.6% IgG+IgM [23].

The present study aimed to provide serological data of recent primary and reactivated HCMV infection among pregnant women attending antenatal clinics of the University of Maiduguri Teaching Hospital, Nigeria and to justify the need for including voluntary CMV screening in antenatal visits.

MATERIAL AND METHODS

Study area. This is a descriptive cross-sectional study, which was carried out in the WHO National Polio Reference Laboratory, University of Maiduguri Teaching Hospital, Borno State, Nigeria. The study was approved by the Ethical Research Committee, University of Maiduguri Teaching Hospital, Nigeria. Maiduguri, the capital city of Borno state, Nigeria, located in northeastern Nigeria shares borders with neighboring countries, such as Niger Republic, Chad, and Cameroon. Within Nigeria, Maiduguri shares borders with other states, such as Adamawa, Yobe, and Gombe and has Sahel savannah vegetation. The annual average temperature of Maiduguri ranges from 19.1°C to 34.7°C and average annual precipitation is 562 mm. In Nigeria, there has been no consensus of opinion regarding conducting CMV screening or other TORCH panel tests for pregnant women during their antenatal visits.

Study population. The study population consisted of pregnant women attending antenatal clinic of the University

of Maiduguri Teaching Hospital, Borno State, Nigeria. The median age of the women was 28 years ranging 16-40 years.

Inclusion criteria. All pregnant women attending antenatal clinic within the study period who consented to participate in the study.

Exclusion criteria. All pregnant women who declined to participate in the study or refused to consent, were excluded.

Sample size. The sample size was determined using prevalence rate demonstrated by Okwori *et al.* [16]. This was 0.842.

Data collection. Questionnaires were used to collect sociodemographic data, such as age, city of residence, gravida, gestational age, educational status, occupation, marital status, number of marriages, history of blood transfusion, and history of congenital deformity.

Sample collection and preparation. Samples were collected between December 2013 and March 2014. Five ml of blood was collected aseptically into plain vacutainer tubes. The tubes were then appropriately labelled with patients' laboratory number. Sera from these blood samples were separated by allowing the blood to clot at room temperature and centrifuged at 2500 rpm for 10 min. The sera were then separated using clean Pasteur pipettes, transferred into serum containers, and stored at -70°C until laboratory analysis.

Laboratory diagnosis. Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) using ELISA CMV IgM and IgG kits (NovaLisa™ Immunodiagnostica, Germany) with product numbers CMVM0110 and CMVG0110, respectively.

Test Procedure. All samples and reagents were brought to room temperature. The test was performed according to manufacturer's instructions. The optical density (OD) was read using a GF-M3000 microplate reader at 450 nm wavelength. Samples were considered positive if the absorbance value was higher than 10% over the cut-off and negative if the absorbance value was lower than 10% below the cut-off. The cut-off is the mean absorbance value of the cut-off control determinations.

Informed consent. The purpose of this work was explained to the participants before obtaining their written consent. The consent form was filled in by the investigators, after which each participants signed her corresponding forms.

Ethical approval. Ethical approval for this study was obtained from the Ethical Committee of the University of Maiduguri Teaching Hospital before embarking on the research.

Statistical analysis. The data obtained from the questionnaire and the results of the laboratory analysis were entered into Microsoft Excel and analyzed using SPSS (statistical package for social sciences, version 20). The results obtained were reduced to percentages and figures. The Pearson Chi square test at a 95% confidence interval and a significance level of 0.05 was used to determine the relationships between demographic data and prevalence rates.

RESULTS

One hundred and eighty-two samples were tested and the study population were attendees of antenatal clinics of the University of Maiduguri Teaching Hospital for their usual periodic check-up. The mean age of the studied women was 25.1±6.66 ranging 16 to 40 years. Thirty-two (17.6%) women were between 15-20 years of age, while fifty-two (28.6%) were between 31-40 years (Table 2a).

Seroprevalence. At the first screening, the results of the serological assays were categorized into 4 types of responses. The first group was immune to CMV [IgG (+) and IgM (-)], which consisted of 141 women. In the second group, three women had reactivated infection [IgG (+) and IgM (+)]. In the third group, there was only one woman who had recent infection [IgG (-) and IgM (+)]. In the fourth group there were 37 women who were susceptible to

CMV infection [IgG (-) but had IgM (-)]. Thus, anti-CMV IgG seropositivity was 79.1% and anti-CMV IgM seropositivity was 2.2% (Table 1).

Table 2a shows the distribution of CMV-specific IgG and IgM seropositivity across ages of pregnant women. CMV IgG seropositivity was mostly observed among those ≥31 years, 49 (26.4%) and least among those 15-20 years, 23 (12.6%).

Table 2b shows the distribution of CMV-specific IgG and IgM seropositivity across educational level of pregnant women. 9 (4.9%) women had no form of formal education, 45 (24.7%) had primary education, 80 (43.9%) had secondary education, while 48 (26.4%) had tertiary education. CMV IgG seropositivity was highest among those with secondary education, 64 (35.1%) and least among those with no formal education, 7 (3.8%).

Table 1. Summary of anti-CMV IgM and IgG antibodies among pregnant women and their corresponding diagnostic interpretation

S/No.	Antibodies reactivity	Number of subjects tested (%)	Interpretation
1	Positive IgG and Negative IgM	141 (77.5)	Previous exposure
2	Positive IgG and Positive IgM	3 (1.6)	Reactivation infection
3	Negative IgG and Positive IgM	1 (0.6)	Recent infection
4	Negative IgG and Negative IgM	37 (20.3)	Susceptible

Table 2a. Human CMV-specific IgG and IgM seropositivity across age distribution of pregnant women

Item	No. of Subjects Tested (%)		No. of Subjects positive for CMV antibodies (%)		
AGE		IgG + and IgM- (%)	IgG+ and IgM+ (%)	IgG- and IgM+ (%)	IgG- and IgM- (%)
15-20	32 (17.6)	23 (12.6)	0 (0.0)	0 (0.0)	9 (4.9)
21-25	52 (28.6)	33 (18.1)	2 (1.1)	1 (0.5)	16 (8.8)
25-30	46 (25.3)	36 (19.8)	0 (0.0)	0 (0.0)	10 (5.5)
≥31	52 (28.6)	49 (26.4)	1 (0.5)	0 (0.0)	2 (1.1)
Total	182 (100)	141 (77.4)	3 (1.6)	1 (0.5)	37 (20.3)

Note: *p*-value=0.5555

Table 2b. Human CMV-specific IgG and IgM seropositivity across educational level of pregnant women

Item	No. of Subjects Tested (%)		No. of Subjects positive for CMV antibodies (%)		
Education		IgG + and IgM- (%)	IgG+ and IgM+ (%)	IgG- and IgM+ (%)	IgG- and IgM- (%)
None	9 (4.9)	7 (3.8)	1 (0.5)	1 (0.5)	0 (0.0)
Primary	45 (24.7)	29 (15.9)	0 (0.0)	0 (0.0)	16 (9.3)
Secondary	80 (43.9)	64 (35.1)	1 (0.5)	0 (0.0)	15 (8.2)
Tertiary	48 (26.4)	41 (22.5)	1 (0.5)	0 (0.0)	6 (3.3)
Total	182 (100)	141 (77.4)	3 (1.6)	1 (0.5)	37 (20.3)

Note: *p*-value= 0.085

Table 2c shows the distribution of CMV-specific IgG and IgM seropositivity across gestational age of pregnant women. Ninety-three (51.1%) women were in their third trimester, 79 (43.4%) were in their second trimester, while only 10 (5.5%) were in the first trimester.

Table 2d shows the distribution of CMV-specific IgG and IgM seropositivity across parity distribution of pregnant women. Fifty-one (28.0%) women were carrying

their first pregnancy (primigravida), 25 (13.7%) had only one child, and 32 (17.6%) had more than 4 children.

There was no significant association between any of the sociodemographic data studied and seroprevalence of HCMV (*p*<0.05).

Figure 1 shows that majority of pregnant women with CMV IgG seropositivity were at their third trimester, 73 (51%), and least among those at their first trimester, 7 (5%).

Table 2c. Human CMV-specific IgG and IgM seropositivity across gestational age of pregnant women

Item	No. of Subjects Tested (%)	No. of Subjects positive for CMV antibodies (%)			
Gestational age		IgG+ and IgM- (%)	IgG+ and IgM+(%)	IgG- and IgM+(%)	IgG- and IgM-(%)
First trimester	10 (5.5)	7 (3.8)	0 (0.0)	0 (0.0)	3 (1.6)
Second trimester	79 (43.4)	61 (33.5)	3 (1.6)	1 (0.5)	14 (7.7)
Third trimester	93 (51.1)	73 (40.1)	0 (0.0)	0 (0.0)	20 (10.9)
Total	182 (100)	141 (77.4)	3 (1.6)	1 (0.5)	37 (20.3)

Note: p -value= 0.085

Table 2d. Human CMV-specific IgG and IgM seropositivity across parity distribution of pregnant women

Item	No. of Subjects Tested (%)	No. of Subjects positive for CMV antibodies (%)			
Parity		IgG + and IgM- (%)	IgG+ and IgM+(%)	IgG- and IgM+(%)	IgG- and IgM-(%)
0	51 (28.0)	41 (22.5)	0 (0.0)	0 (0.0)	10 (5.5)
1	25 (13.7)	16 (8.8)	1 (0.5)	0 (0.0)	8 (4.4)
2	33 (18.1)	23 (12.6)	0 (0.0)	0 (0.0)	10 (5.5)
3	19 (10.4)	11 (6.0)	0 (0.0)	0 (0.0)	8 (4.4)
4	22 (12.1)	18 (9.9)	2 (1.1)	1 (0.0)	1 (0.5)
≥ 5	32 (17.6)	32 (17.6)	0 (0.0)	0 (0.0)	0 (0.0)
Total	182 (100)	141 (77.4)	3 (1.6)	1 (0.5)	37 (20.3)

Note: p -value=0.06667

IgG = Immunoglobulin G
+ = Seropositivity

IgM = Immunoglobulin M
- = Seronegativity




Fig. 1. Pie chart representation of anti-CMV IgG seropositivity across gestational age

DISCUSSION

The findings of this study revealed that 77.5% of the pregnant women had anti-CMV IgG with no corresponding anti-CMV IgM antibodies. Development of IgG antibodies to CMV indicates that these women had previous infection with CMV in their life time. The level of maternal immunity observed in this study compares favorably with the findings of previous studies in Nigeria and other developing countries [24-27]; however, it differs from those

reported in developed countries, where seroprevalence rates were lower (58% and 49%) [28, 29].

The differences in the prevalence of maternal CMV infection between developed and developing countries may reflect the ignorance on the disease and low hygienic standard and cultural practices, which can increase infection transmission in developing countries. It is likely that in developed countries, pregnant women are generally more informed on the disease, good hygienic practices, and

other preventive measures, which account for a reduced risk of acquiring CMV infection. In addition, the high socioeconomic status of women in developed countries could account for this difference, due to the higher risk of primary maternal infection in women with low socioeconomic status than in those with high socioeconomic status [30]. Ludwig and Hengel observed that low socioeconomic status is a risk factor for congenital CMV infection.

There was an exponential increase in the prevalence of CMV IgG during the first (7%), second (61%), and third trimesters (73%) of the pregnancies. Three (3.8%) women had reactivated CMV infection (positive for both anti-CMV IgG and IgM antibodies) during the second trimester. These are not considered primary HCMV infection; this speculation is supported by a report showing that a significant increase in anti-CMV specific IgG antibody titre with or without the presence of specific IgM antibodies is an indication of non-primary CMV, which must have been acquired before pregnancy [31].

Seo *et al.* demonstrated that pregnant women who were positive for both CMV IgG and IgM antibodies, also had high IgG avidity index, and were at low risk of transmitting CMV infection [32]. In their report, none of the neonates of the women showed evidence of congenital CMV infection on routine neonatal examination. In our study, IgG avidity test was not performed on the 3 women who had both anti-CMV IgG and IgM. This was due to subsequent closure of Maiduguri neighbouring borders, where IgG avidity ELISA kit can be delivered to us if purchased, as a result of security tension.

The study by Ludwig and Hengel showed that the overall CMV seroprevalence in women of childbearing age depends on age, ethnicity, parity, and social status, and is different between countries and regions. In contrast to that report, seroprevalence in our study was not significantly associated with age, parity, gestational age, and educational status of the women studied. Further studies with larger sample size are required to determine the actual association between CMV antibody prevalence and these sociodemographic data.

In this study, 3 (1.6%), 14 (7.7%), and 20 (10.9%) of the pregnant women were non-immune (IgG- and IgM-) during their first, second, and third trimesters, respectively. They are at risk of acquiring primary infection, which increases the chances of intrauterine transmission to fetus [33]. Women infected with CMV during late gestation are most likely to transmit the virus to their unborn child than women infected early in gestation. Failure to detect seroconversions in late gestation may lead to failure to detect infected asymptomatic neonates [33].

It is therefore imperative for pregnant women to be informed of hygienic practices and behavioral measures, such as avoiding direct contact with organic materials and frequent thorough hand-washing, which can reduce the chance of infection [34].

Although, anti-CMV IgM antibodies are good indicator of recent infection, it does not always correlate with primary infection. This is because pregnant women can

produce IgM during reactivations or reinfections. Virus-specific IgM may persist for months after natural infection and can be detected in pregnant women, 6-12 months after the end of the acute phase of primary infection [2, 35]. In addition, false-positive results are common and may arise in patients with other viral infections (*e.g.* parvovirus B19 and Epstein-Barr virus) or autoimmune diseases or due to interference with rheumatoid factor of the IgM class, or laboratory methods used [32]. Usually, all positive CMV IgM should be tested for low avidity IgG antibodies, which can persist for up to 20 weeks after primary infection, and then they are replaced by high avidity IgG antibodies. Therefore, our inability to perform IgG avidity test on the CMV IgM positive women, due to limited resources renders this result inconclusive in terms of the primary CMV infection status. Nevertheless, there is a need to follow-up these cases through neonatal examination.

The low prevalence (0.5%) of recent infection (anti-CMV IgM seropositivity) in this study is in agreement with other studies [35, 36]. However, higher seroprevalences have been documented by other researchers [37, 38]. These discrepancies may be attributed to differences in socio-demographic setting and this can be inferred from the work of Stagno and Whitley, which demonstrated that the risk of primary maternal infection was approximately three times higher among the high-income susceptible women (45%) compared to the low-income groups (15%). This may be viewed from the point that there are likely more seronegative women among those with higher educational background (especially tertiary education), due to better hygiene compared to those with lower social class and educational background, making the former more susceptible to primary infection. However, it would be reasonable to study a larger sample size of this group to obtain a meaningful conclusion on risk factors.

The low prevalence of IgM antibodies observed in this study may also be due to the fact that majority of the women would have recovered from primary infection, with loss of IgM, by the time they reach child bearing age [39]. Although, the prevalence of recent infection among pregnant women is low, they are a critical group because the risk of congenital CMV infection is much higher during recent infection in the mother [40, 41].

Therefore, it would be beneficial to properly inform this category of women on the need for further investigations, such as ultrasonography, magnetic resonance imaging and amniocentesis to detect prenatal infection and planning of proper interventions, such as use of hyperimmune globulin or termination of pregnancy.

In Nigeria and most other countries, routine screening is not widely used for maternal CMV infection, while prenatal CMV screening remains controversial and has not been approved by any professional organization or public health authority worldwide [42, 43]; however, in some European countries and in Israel, prenatal CMV testing is more widely performed, even if there are no recommendations for routine screening [43]. Our study indicates that CMV screening in pregnant women may gain more importance in the future antenatal care, and diagnostic value of readily

accessible serologic tests would be known in the future. Moreover, there is need to perform other CMV diagnostic tests, such as IgG avidity test, cytokine assays, and polymerase chain reaction in order to confirm CMV infection status in these pregnant women.

ACKNOWLEDGEMENT

We will like to acknowledge Mr. Bamidele Oderinde and Mr. Ajayi Babajide of the departments of Immunology and Medical Laboratory Sciences, University of Maiduguri Teaching Hospital, Nigeria for their technical support.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest associated with this manuscript.

REFERENCES

1. Bodéus M, Feyder S, Goubau P. Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infection in pregnant women. *Clin Diagn Virol*. 1998; 9 (1): 9-16.
2. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. *Clin Microbiol Rev*. 2002; 15 (4): 680-715.
3. Roback JD. CMV and blood transfusions. *Rev Med Virol*. 2002; 12 (4): 211-9.
4. Chaudhari CN, Bindra MS. Seroprevalence of Cytomegalovirus among voluntary blood donors. *Med J Armed Forces India*. 2009; 65 (3): 252-4.
5. Riley HD Jr. History of the cytomegalovirus. *South Med J*. 1997; 90 (2): 184-90.
6. Ho M. The History of Cytomegalovirus and its Diseases. *Med Microbiol Immunol*. 2008; 197 (2): 65-73.
7. Goodpasture EW, Talbot FB. Concerning the nature of 'protozoan-like' cells in certain lesions of infancy. *Am J Dis Child*. 1921; 21 (5): 415-25.
8. Smith M G. Propagation of salivary gland virus of the mouse in tissue cultures. *Proc Soc Exp Biol Med*. 1954; 86 (3): 435-40.
9. Rowe WP, Hartley JW, Waterman S, Turner HC, Huebner RJ. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. *Proc Soc Exp Biol Med*. 1956; 92 (2): 418-24.
10. Craig JM, Macauley JC, Weller TH, Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. *Proc Soc Exp Biol Med*. 1957; 94 (1): 4-12.
11. Schleiss MR. Paediatric Cytomegalovirus Infection. *eMedicine Specialties Pediatric General Medicine*. [homepage of internet]. 2010. Available from: www.eMedicinemedscape.com/Pediatric-generalInfections [cited 2014 Dec 20].
12. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. *BMC Infect Dis*. 2007; 7: 71.
13. Pass RF, Hutto C, Ricks K, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. *N Engl J Med*. 1986; 314 (22): 1414-8.
14. Ludwig A, Hengel H. Epidemiological Impact and Disease Burden of Congenital Cytomegalovirus Infection in Europe. *Euro Surveill*. 2009; 14 (9): 26-32.
15. Matos SB, Meyer R, Lima WM. Seroprevalence of Cytomegalovirus infection among healthy blood donors in Bahia State, Brazil. *Rev Bras Hematol Hemoter*. 2010; 32 (1): 45-9.
16. Okwori A, Olabode A, Emumwen E, Echeonwu G, Lugos M, Okpe E, Okopi J, Adetunji J. Sero-Epidemiological Survey of Cytomegalovirus Infection among expectant Mothers in Bida, Nigeria. *J Infect Dis*. 2008; 7 (1): 1-9.
17. Seferi I, Xhumari P, Burazeri G. Prevalence of Cytomegalovirus in paid and unpaid blood donor population in Tirana. *J Health Sci*. 2009; 2 (4): 251-5.
18. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the influence of parity. *Arch Dis Child*. 1992; 67 (7 Spec No): 779-83.
19. Hollier LM, Grissom H. Human herpes viruses in pregnancy; cytomegalovirus, Epstein-Barr virus and varicella-zoster virus. *Clin Perinatol*. 2005; 32 (3): 671-96.
20. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus infection. *Rev Med Virol*. 2007; 17 (4): 253-76.
21. Gratacap-Cavallier B, Bosson JL, Morand P, Dutertre N, Chanzy B, Jouk PS, Vandekerckhove C, Cart-Lamy P, Seigneurin JM. Cytomegalovirus seroprevalence in French pregnant women. Parity and place of birth as major predictive factors. *Eur J Epidemiol*. 1998; 14 (2): 147-52.
22. Akinbami AA, Rabi KA, Adewunmi AA, Wright KO, Dosunmu AO, Adeyemo TA, Adediran A, Osunkalu VO. Seroprevalence of CMV antibodies among normal pregnant women in Nigeria. *Int J Womens Health*. 2011; 3: 423-8.
23. Tamer GS, Dundar D, Caliskan E. Seroprevalence of Toxoplasma gondii, Rubella and Cytomegalovirus among pregnant women in Western region of Turkey. *Clin Invest Med*. 2009; 32 (1): E43-7.
24. Ahmad RM, Kawo AH, Udeani TKC, Manga SB, Ibrahim ML, Danjuma B. Sero-prevalence of Cytomegalovirus antibodies in pregnant women attending two selected hospitals in Sokoto State, North Western Nigeria. *Bayero Journal of Pure and Applied Sciences*. 2011; 4 (1): 63-6.
25. Turbadkar M, Mathur M, Rele M. Seroprevalence of TORCH infection in bad obstetric history. *Indian J Med Microbiol*. 2003; 21 (2): 108-10.
26. Ephraim O, Oyinola O, Patrick VL, Joseph UO, Charles JE. Seroprevalence and risk factors for cytomegalovirus infection among pregnant women in southern Nigeria. *J Microbiol Infect Dis*. 2013; 3 (3): 123-7.
27. Dollard SC, Staras SA, Amin MM, Schmid DS, Cannon MJ. National prevalence estimate for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titre and Low IgG avidity. *Clin Vaccine Immunol*. 2011; 18 (11): 1895-9.
28. Pembrey L, Raynor P, Griffiths P, Chaytor S, Wright J, Hall AJ. Seroprevalence of Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus among Pregnant Women in Bradford: A Cohort Study. *PLoS ONE*. 2013; 8 (11): e81881.
29. Stagno S, Whitley RJ. Herpesvirus infection of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. *N Engl J Med*. 1985; 313 (20): 1270-4.

30. Lazzarott T, Gabrielli L, Lanari M, Guerra B, Bellucci T, Sassi M, Landini MP. Congenital Cytomegalovirus Infection: Recent Advances in the Diagnosis of maternal Infection. *Hum Immol*. 2004; 65 (5): 410-14.
31. Seo S, Cho Y, Park J. Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test. *Korean J Lab Med*. 2009; 29 (6): 557-62.
32. Munro SC, Hall B, Whybin LR, Leader L, Robertson P, Maine GT, Rawlinson WD. Diagnosis of and Screening for Cytomegalovirus Infection in Pregnant Women. *J Clin Microbiol*. 2005; 43 (9): 4713-8.
33. Forsgren M. prevention of congenital and perinatal infections. *Euro Surveill*. 2009; 14 (9): 1-6.
34. Adler SP, Marshall B. Cytomegalovirus infections. *Pediatr Rev*. 2007; 28 (3): 92-100.
35. Hamdan ZH, Abdelbagi IE, Nasser NM, Adam I. Seroprevalence of cytomegalovirus and rubella among pregnant women in Western Sudan. *Virol J*. 2011; 8: 217.
36. Stagno S. Cytomegalovirus in Infectious Diseases of the Fetus and Newborn Infant. Remington JS, Klein JO, editors. Philadelphia: WB Saunders Co. 2001; 389-424.
37. Tabatabaee M, Tayyebi D. Seroepidemiologic study of human cytomegalovirus in pregnant women in Valiasr hospital of Kazeroon, Fars. *J Matern Fetal Neonatal Med*. 2009; 22 (6): 517-21.
38. Rahav G, Gabbay R, Ornoy A, Shechtman S, Aron J, Diav-Citrin O. Primary versus nonprimary cytomegalovirus infection during pregnancy. *Emerg Infect Dis*. 2007; 13 (11): 1791-3.
39. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevalence of congenital cytomegalovirus infection. *JAMA*. 2003; 289 (8): 1008-11.
40. Cahill AG, Odibo AO, Stamilio DM, Macones GA. Screening and testing for primary cytomegalovirus in pregnancy: where do we stand? A decision-analytic and economic analysis. *Am J Obstet Gynecol*. 2009; 201(5): 466.e1-7.
41. Yinon Y, Farine D, Yudin MH, Gagnon R, Hudon L, Basso M, Bos H, Delisle MF, Menticoglou S, Mundle W, Ouellet A, Pressey T, et al. Cytomegalovirus infection in pregnancy. *J Obstet Gynaecol Can*. 2010; 32 (4): 348-54.
42. Schlesinger Y. Routine screening for CMV in pregnancy: opening the pandora box?. *Isr Med Assoc J*. 2007; 9 (5): 395-7.
43. Revello MG, Fabbri E, Furione M, Zavattoni M, Lilleri D, Tassis B, Quarenghi A, Cena C, Arossa A, Montanari L, Rognoni V, Spinillo A, et al. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. *J Clin Virol*. 2011; 50 (4): 303-7.